Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

14 May 2026, 10:46 by Renee Jackson · The Cerbat Gem

Humacyte (NASDAQ:HUMA – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01, Zacks reports. Humacyte had a negative return on equity of 990.48% and a negative net margin of 1,998.87%.The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $1.46 million.

Here are the key takeaways from Humacyte’s conference call:

Symvess sales increased to $0.5 million in Q1 2026 from $0.1 million a year ago, but management said adoption is still too slow and that stronger commercial execution is needed.
The company reshaped its commercial organization with new senior hires, including a Chief Commercial Officer and Chief Surgical Officer, to improve surgeon education, hospital penetration, and IDN coverage.
Humacyte said its dialysis access Phase III trial is on track for top-line interim results around June 11, with 120 patients enrolled and a supplemental BLA planned for the second half of 2026 if results are positive.
The company restructured its workforce in May, cutting 45 employees, and expects about $0.8 million in severance charges despite projecting roughly $14.3 million in savings for the rest of 2026.
Humacyte ended Q1 with $48.9 million in cash and restricted cash; however, it reported a $17.6 million net loss, driven largely by lower non-cash income from contingent earn-out remeasurement.

Humacyte Price Performance

HUMA traded down $0.10 during trading hours on Thursday, hitting $1.04. The company’s stock had a trading volume of 3,324,625 shares, compared to its average volume of 6,460,723. Humacyte has a 12 month low of $0.55 and a 12 month high of $2.93. The stock has a market cap of $229.79 million, a price-to-earnings ratio of -5.18 and a beta of 2.31. The business’s 50-day moving average price is $0.86 and its 200-day moving average price is $1.07. The company has a current ratio of 3.69, a quick ratio of 2.95 and a debt-to-equity ratio of 20.08.

Wall Street Analyst Weigh In

Several analysts have issued reports on HUMA shares. Benchmark cut their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 21st. Wall Street Zen downgraded Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 11th. D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday, April 28th. TD Cowen reaffirmed a “buy” rating on shares of Humacyte in a report on Thursday. Finally, BTIG Research dropped their price target on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.57.

Get Our Latest Research Report on HUMA

Hedge Funds Weigh In On Humacyte

Institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace LLP raised its holdings in Humacyte by 5,308.2% during the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after buying an additional 2,590,394 shares during the period. Millennium Management LLC boosted its stake in Humacyte by 129.5% during the fourth quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock worth $2,528,000 after buying an additional 1,485,152 shares during the period. Geode Capital Management LLC increased its position in Humacyte by 33.4% during the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after acquiring an additional 738,142 shares during the last quarter. Barclays PLC increased its position in Humacyte by 298.7% during the fourth quarter. Barclays PLC now owns 729,469 shares of the company’s stock valued at $701,000 after acquiring an additional 546,491 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Humacyte by 7.4% in the third quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company’s stock valued at $13,085,000 after acquiring an additional 520,431 shares during the period. Hedge funds and other institutional investors own 44.71% of the company’s stock.

More Humacyte News

Here are the key news stories impacting Humacyte this week:

Positive Sentiment: Humacyte said first-quarter sales of Symvess rose to $0.5 million from $0.1 million a year ago, and it highlighted commercial progress including a Saudi purchase commitment, Israeli regulatory acceptance for Symvess, DoD funding, and an upcoming Phase 3 readout for its hemodialysis program.
Positive Sentiment: BTIG Research maintained a buy rating on HUMA, though it lowered its price target to $2.00 from $3.00, suggesting analysts still see upside despite the recent setback. BTIG price target cut coverage
Neutral Sentiment: Humacyte appointed new commercial and surgical leadership, including a Chief Commercial Officer and Chief Surgical Officer, as it looks to improve execution and expand adoption.
Negative Sentiment: Q1 revenue of about $0.49 million missed the $1.46 million consensus estimate by a wide margin, reinforcing concerns that commercial traction is still limited. Q1 earnings miss coverage
Negative Sentiment: Reports that Humacyte is cutting spending and staff to support sales growth and manage cash are adding to investor caution. Layoff and spending cuts coverage

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.